Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
By M. Cristofanilli, D. Hayes, G. Budd, M. Ellis, A. Stopeck, J. Reuben, G. Doyle, J. Matera, W. Allard, M. Miller and 3 more. Journal of Clinical Oncology, 2005
1,126 citations recorded by the source corpus.
Subfields: Oncology, Psychiatry and Mental health, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/91e0d89947fc3b7a6b2bb7af641e2b4ca61fdebd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer (2007, neutral): “patients 8 30 13 15 25 29 Percent (7) (25) (11) (12) (21) (24)”
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007, background): “Similarly, the presence of more than five CTCs after the first course of hormone therapy or chemotherapy predicts for no treatment response.(315,318) A subsequent report from Hayes et al(319) showed that the detection of more than five CTCs at any time during therapy was indicative of treatment fail”
- Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival (2006, background): “Recently, we reported the results of a prospective, multicenter trial that showed that circulating tumor cell (CTC) levels before starting a new therapy and at first follow-up were a strong predictor of rapid progression and death in patients with MBC about to start any new systemic therapy (5) and ”
- Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer (2006, background): “<5 CTC 103 (75) 5/101 (5) 16/97 (16) 22.”